.Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX22_Agomelatine.Agomelatine .Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX22_Agomelatine.Agomelatine| name: | Agomelatine |
| ATC code: | N06AX22 | route: | oral |
| n-compartments | 1 |
Agomelatine is an antidepressant that acts as an agonist at melatonergic MT1 and MT2 receptors and as an antagonist at 5-HT2C serotonin receptors. It is used primarily in the treatment of major depressive disorder in adults. Agomelatine is approved in several countries for clinical use in depression.
Pharmacokinetic parameters summarized for healthy adult subjects after oral administration as single and multiple doses.
Xie, F, et al., & Cheng, Z (2019). A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers. British journal of clinical pharmacology 85(5) 1003–1014. DOI:10.1111/bcp.13902 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30761579
Song, L, et al., & Wang, L (2014). Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. Journal of clinical pharmacy and therapeutics 39(2) 204–209. DOI:10.1111/jcpt.12118 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24372004
ElKady, EF, et al., & Farouk, F (2018). Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 1102-1103 135–142. DOI:10.1016/j.jchromb.2018.10.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30388703